Anavex Life Sciences Corp
AVXL10.020USD
-0.240-2.34%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
855.83MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Anavex Life Sciences Corp Unternehmen
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with high unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. It has two core programs and two seed programs. ANAVEX 2-73 is being developed as an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease. ANAVEX 3-71 is a CNS-penetrable potential disease-modifying treatment for cognitive impairments. Its other candidates include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037.
Unternehmensinformationen
BörsenkürzelAVXL
Name des UnternehmensAnavex Life Sciences Corp
IPO-datumApr 13, 2006
CEODr. Christopher U. Missling, Ph.D.
Anzahl der mitarbeiter42
WertpapierartOrdinary Share
GeschäftsjahresendeApr 13
Addresse630 5Th Avenue
StadtNEW YORK
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl10111
Telefon18446893939
Websitehttps://www.anavex.com
BörsenkürzelAVXL
IPO-datumApr 13, 2006
CEODr. Christopher U. Missling, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Christopher U. Missling, Ph.D.
Dr. Christopher U. Missling, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
1.47M
--
Mr. Athanasios (Tom) Skarpelos
Mr. Athanasios (Tom) Skarpelos
Independent Director
Independent Director
1.31M
--
Ms. Sandra Boenisch, CPA
Ms. Sandra Boenisch, CPA
Principal Financial Officer, Treasurer
Principal Financial Officer, Treasurer
22.96K
--
Dr. Claus van Der Velden, Ph.D.
Dr. Claus van Der Velden, Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter Donhauser, M.D.
Dr. Peter Donhauser, M.D.
Independent Director
Independent Director
--
--
Ms. Jiong Ma, Ph.D.
Ms. Jiong Ma, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Steffen Thomas, Ph.D.
Dr. Steffen Thomas, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Christopher U. Missling, Ph.D.
Dr. Christopher U. Missling, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
1.47M
--
Mr. Athanasios (Tom) Skarpelos
Mr. Athanasios (Tom) Skarpelos
Independent Director
Independent Director
1.31M
--
Ms. Sandra Boenisch, CPA
Ms. Sandra Boenisch, CPA
Principal Financial Officer, Treasurer
Principal Financial Officer, Treasurer
22.96K
--
Dr. Claus van Der Velden, Ph.D.
Dr. Claus van Der Velden, Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter Donhauser, M.D.
Dr. Peter Donhauser, M.D.
Independent Director
Independent Director
--
--
Ms. Jiong Ma, Ph.D.
Ms. Jiong Ma, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Aug 16
Aktualisiert: Sat, Aug 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
7.24%
The Vanguard Group, Inc.
5.92%
State Street Global Advisors (US)
3.43%
Geode Capital Management, L.L.C.
2.35%
Two Sigma Investments, LP
2.09%
Andere
78.96%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
7.24%
The Vanguard Group, Inc.
5.92%
State Street Global Advisors (US)
3.43%
Geode Capital Management, L.L.C.
2.35%
Two Sigma Investments, LP
2.09%
Andere
78.96%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
23.80%
Investment Advisor/Hedge Fund
9.48%
Individual Investor
3.31%
Hedge Fund
3.04%
Research Firm
1.07%
Bank and Trust
0.83%
Pension Fund
0.22%
Insurance Company
0.04%
Andere
58.22%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
355
34.98M
40.98%
-162.00K
2025Q1
362
35.10M
41.13%
+789.16K
2024Q4
351
32.45M
38.14%
-89.26K
2024Q3
337
29.80M
35.14%
-2.92M
2024Q2
337
29.64M
35.02%
-6.78M
2024Q1
332
34.88M
42.48%
+4.38M
2023Q4
335
28.85M
35.15%
-996.59K
2023Q3
331
28.07M
34.33%
-2.23M
2023Q2
335
28.30M
35.04%
-4.91M
2023Q1
340
29.94M
37.61%
-3.19M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
5.98M
7%
+20.29K
+0.34%
Mar 31, 2025
The Vanguard Group, Inc.
4.88M
5.72%
+202.97K
+4.34%
Mar 31, 2025
State Street Global Advisors (US)
3.21M
3.77%
+802.33K
+33.26%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.96M
2.3%
+89.89K
+4.79%
Mar 31, 2025
Two Sigma Investments, LP
1.37M
1.6%
+100.80K
+7.95%
Mar 31, 2025
Missling (Christopher U)
1.47M
1.72%
--
--
Apr 25, 2025
Skarpelos (Athanasios)
1.31M
1.53%
--
--
Apr 25, 2025
Northwest Asset Management
1.00M
1.17%
+87.30K
+9.56%
Mar 31, 2025
Invesco Capital Management LLC
515.07K
0.6%
-77.48K
-13.08%
Mar 31, 2025
Northern Trust Investments, Inc.
674.75K
0.79%
-26.63K
-3.80%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
